UNSPSC 51392304: Xamoterol

This classification denotes a beta-adrenergic agonist with the molecular formula C16H25N3O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7HE0JQL703, chemically known as 4-morpholinecarboxamide, n-(2-((2-hydroxy-3-(4-hydroxyphenoxy)propyl)amino)ethyl)-, (+-)- but generally known as xamoterol, which bears US NIH Compound Identifier 155774. European Medicines Agency schedules Xamoterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00092MIG.

UNSPSC 51392304 Xamoterol is a Commodity code that state and local governments are using to procure emergency-response pharmaceuticals and related medical supplies, specifically naloxone and drug deactivation systems for community health and overdose-prevention programs. The recent activity shows county health departments and state health agencies sourcing these medications and systems through competitive bidding processes tied to public health initiatives. Issuing bodies include county governments operating community health services and state health and human services commissions managing pharmacy benefit and therapeutic programs. Seminole County, Florida represents the traditional procurement path—direct purchase of naloxone units and safe drug deactivation systems for quarterly delivery to county health facilities, supporting overdose-response capacity.

Recent opportunities span Florida and Texas. Seminole County issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through an IFB with a July 26, 2023 deadline, with quarterly delivery to the Seminole County Community Health Building in Sanford, and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, gathering vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program that would establish direct contracting between the state's pharmacy benefit program and pharmaceutical manufacturers, seeking information on vendors' experience with direct contracting, negotiated net pricing models, and value-based agreements for self-insured employers and state agencies. Both solicitations indicate state and local focus on direct pharmaceutical sourcing and cost management through centralized procurement mechanisms.